Schonfeld Strategic Advisors LLC Aurinia Pharmaceuticals Inc. Transaction History

Schonfeld Strategic Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $388,278 - $722,337	58,300 Added 126.19%	104,500 $787,000
Q2 2022 Aug 15, 2022	BUY	$8.95 - $12.8 $413,489 - $591,360	46,200 New	46,200 $465,000
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $922,782 - $1.72 Million	-51,900 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$10.93 - $23.55 $267,785 - $576,975	24,500 Added 89.42%	51,900 $1.15 Million
Q2 2021 Aug 16, 2021	BUY	$10.0 - $14.52 $67,000 - $97,284	6,700 Added 32.37%	27,400 $354,000
Q1 2021 May 17, 2021	BUY	$12.3 - $18.73 $254,610 - $387,711	20,700 New	20,700 $269,000
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $1.19 Million - $1.48 Million	-92,100 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $1.21 Million - $1.53 Million	92,100 New	92,100 $1,000
Q1 2020 May 15, 2020	SELL	$11.34 - $21.46 $3.54 Million - $6.7 Million	-312,268 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $1.21 Million - $6.69 Million	312,268 New	312,268 $6.33 Million

191

56.2M

499K

637K

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.03B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.